158 related articles for article (PubMed ID: 29482584)
1. Differential cyclooxygenase expression levels and survival associations in type I and type II ovarian tumors.
Beeghly-Fadiel A; Wilson AJ; Keene S; El Ramahi M; Xu S; Marnett LJ; Fadare O; Crispens MA; Khabele D
J Ovarian Res; 2018 Feb; 11(1):17. PubMed ID: 29482584
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of the embryonic-lethal abnormal vision-like protein HuR in ovarian carcinoma is a prognostic factor and is associated with increased cyclooxygenase 2 expression.
Denkert C; Weichert W; Pest S; Koch I; Licht D; Köbel M; Reles A; Sehouli J; Dietel M; Hauptmann S
Cancer Res; 2004 Jan; 64(1):189-95. PubMed ID: 14729623
[TBL] [Abstract][Full Text] [Related]
3. Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study.
Sieh W; Köbel M; Longacre TA; Bowtell DD; deFazio A; Goodman MT; Høgdall E; Deen S; Wentzensen N; Moysich KB; Brenton JD; Clarke BA; Menon U; Gilks CB; Kim A; Madore J; Fereday S; George J; Galletta L; Lurie G; Wilkens LR; Carney ME; Thompson PJ; Matsuno RK; Kjær SK; Jensen A; Høgdall C; Kalli KR; Fridley BL; Keeney GL; Vierkant RA; Cunningham JM; Brinton LA; Yang HP; Sherman ME; García-Closas M; Lissowska J; Odunsi K; Morrison C; Lele S; Bshara W; Sucheston L; Jimenez-Linan M; Driver K; Alsop J; Mack M; McGuire V; Rothstein JH; Rosen BP; Bernardini MQ; Mackay H; Oza A; Wozniak EL; Benjamin E; Gentry-Maharaj A; Gayther SA; Tinker AV; Prentice LM; Chow C; Anglesio MS; Johnatty SE; Chenevix-Trench G; Whittemore AS; Pharoah PD; Goode EL; Huntsman DG; Ramus SJ
Lancet Oncol; 2013 Aug; 14(9):853-62. PubMed ID: 23845225
[TBL] [Abstract][Full Text] [Related]
4. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
5. High MUC2 expression in ovarian cancer is inversely associated with the M1/M2 ratio of tumor-associated macrophages and patient survival time.
He YF; Zhang MY; Wu X; Sun XJ; Xu T; He QZ; Di W
PLoS One; 2013; 8(12):e79769. PubMed ID: 24324582
[TBL] [Abstract][Full Text] [Related]
6. COX-2 expression pattern is related to ovarian cancer differentiation and prognosis, but is not consistent with new model of pathogenesis.
Magnowska M; Zaborowski M; Surowiak P; Nowak-Markwitz E; Zabel M; Spaczyński M
Ginekol Pol; 2014 May; 85(5):335-41. PubMed ID: 25011213
[TBL] [Abstract][Full Text] [Related]
7. EP1-4 subtype, COX and PPAR gamma receptor expression in colorectal cancer in prediction of disease-specific mortality.
Gustafsson A; Hansson E; Kressner U; Nordgren S; Andersson M; Wang W; Lönnroth C; Lundholm K
Int J Cancer; 2007 Jul; 121(2):232-40. PubMed ID: 17290397
[TBL] [Abstract][Full Text] [Related]
8. The effect of cyclooxygenase-2 expression on tumor vascularity in advanced stage ovarian serous carcinoma.
Ali-Fehmi R; Che M; Khalifeh I; Malone JM; Morris R; Lawrence WD; Munkarah AR
Cancer; 2003 Oct; 98(7):1423-9. PubMed ID: 14508829
[TBL] [Abstract][Full Text] [Related]
9. High levels of pretreatment CA125 are associated to improved survival in high grade serous ovarian carcinoma.
Morales-Vásquez F; Pedernera E; Reynaga-Obregón J; López-Basave HN; Gómora MJ; Carlón E; Cárdenas S; Silva-Ayala R; Almaraz M; Méndez C
J Ovarian Res; 2016 Jul; 9(1):41. PubMed ID: 27388275
[TBL] [Abstract][Full Text] [Related]
10. Prognostic impact of HER3 based on protein and mRNA expression in high-grade serous ovarian carcinoma.
Unger U; Denkert C; Braicu I; Sehouli J; Dietel M; Loibl S; Darb-Esfahani S
Virchows Arch; 2017 Feb; 470(2):143-151. PubMed ID: 27913862
[TBL] [Abstract][Full Text] [Related]
11. Vascular endothelial growth factor (VEGF) and cyclooxygenase 2 (COX 2) immunostaining in ovarian cancer.
Whynott RM; Manahan P; Geisler JP
Eur J Gynaecol Oncol; 2016; 37(2):164-6. PubMed ID: 27172738
[TBL] [Abstract][Full Text] [Related]
12. High expression of NQO1 is associated with poor prognosis in serous ovarian carcinoma.
Cui X; Li L; Yan G; Meng K; Lin Z; Nan Y; Jin G; Li C
BMC Cancer; 2015 Apr; 15():244. PubMed ID: 25885439
[TBL] [Abstract][Full Text] [Related]
13. Prognostic impact of concomitant p53 and PTEN on outcome in early stage (FIGO I-II) epithelial ovarian cancer.
Skírnisdóttir I; Seidal T
Int J Gynecol Cancer; 2011 Aug; 21(6):1024-31. PubMed ID: 21792012
[TBL] [Abstract][Full Text] [Related]
14. Low MAD2 expression levels associate with reduced progression-free survival in patients with high-grade serous epithelial ovarian cancer.
Furlong F; Fitzpatrick P; O'Toole S; Phelan S; McGrogan B; Maguire A; O'Grady A; Gallagher M; Prencipe M; McGoldrick A; McGettigan P; Brennan D; Sheils O; Martin C; W Kay E; O'Leary J; McCann A
J Pathol; 2012 Apr; 226(5):746-55. PubMed ID: 22069160
[TBL] [Abstract][Full Text] [Related]
15. The NER-related gene GTF2H5 predicts survival in high-grade serous ovarian cancer patients.
Gayarre J; Kamieniak MM; Cazorla-Jiménez A; Muñoz-Repeto I; Borrego S; García-Donas J; Hernando S; Robles-Díaz L; García-Bueno JM; Ramón Y Cajal T; Hernández-Agudo E; Heredia Soto V; Márquez-Rodas I; Echarri MJ; Lacambra-Calvet C; Sáez R; Cusidó M; Redondo A; Paz-Ares L; Hardisson D; Mendiola M; Palacios J; Benítez J; García MJ
J Gynecol Oncol; 2016 Jan; 27(1):e7. PubMed ID: 26463438
[TBL] [Abstract][Full Text] [Related]
16. A DNA repair pathway-focused score for prediction of outcomes in ovarian cancer treated with platinum-based chemotherapy.
Kang J; D'Andrea AD; Kozono D
J Natl Cancer Inst; 2012 May; 104(9):670-81. PubMed ID: 22505474
[TBL] [Abstract][Full Text] [Related]
17. Invasive Epithelial Ovarian Cancer Survival by Histotype and Disease Stage.
Peres LC; Cushing-Haugen KL; Köbel M; Harris HR; Berchuck A; Rossing MA; Schildkraut JM; Doherty JA
J Natl Cancer Inst; 2019 Jan; 111(1):60-68. PubMed ID: 29718305
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of tissue protein expression levels of MIB-1 (Ki-67) in Danish ovarian cancer patients. From the 'MALOVA' ovarian cancer study.
Heeran MC; Høgdall CK; Kjaer SK; Christensen L; Jensen A; Blaakaer J; Christensen IJ; Høgdall EV
APMIS; 2013 Dec; 121(12):1177-86. PubMed ID: 23594232
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of carbonic anhydrase IX (CAIX) is an independent unfavorable prognostic marker in endometrioid ovarian cancer.
Choschzick M; Oosterwijk E; Müller V; Woelber L; Simon R; Moch H; Tennstedt P
Virchows Arch; 2011 Aug; 459(2):193-200. PubMed ID: 21691815
[TBL] [Abstract][Full Text] [Related]
20. Prognostic and predictive values of Nrf2, Keap1, p16 and E-cadherin expression in ovarian epithelial carcinoma.
Liew PL; Hsu CS; Liu WM; Lee YC; Lee YC; Chen CL
Int J Clin Exp Pathol; 2015; 8(5):5642-9. PubMed ID: 26191276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]